FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094341752> ?p ?o ?g. }

• W2094341752 endingPage "e95968" @default.
• W2094341752 startingPage "e95968" @default.
• W2094341752 abstract "Background Amifostine is the most clinical used chemical radioprotector, but its effect in patients treated with radiation is not consistent. Methods By searching Medline, CENTRAL, EMBASE, ASCO, ESMO, and CNKI databases, the published randomized controlled trials (RCTs) about the efficacy of amifostine in HNSCC patients treated with radiotherapy were collected. The pooled efficacy and side effects of this drug were calculated by RevMan software. Results Seventeen trials including a total of 1167 patients (604 and 563 each arm) were analyzed in the meta-analysis. The pooled data showed that the use of amifostine significantly reduce the risk of developing Grade3–4 mucositis (relative risk [RR],0.72; 95% confidence interval [CI],0.54–0.95; p<0.00001), Grade 2–4 acute xerostomia (RR,0.70; 95%CI,0.52–0.96; p = 0.02), or late xerostomia (RR,0.60; 95%CI,0.49–0.74; p<0.00001) and Grade 3–4 dysphagia (RR,0.39; 95%CI,0.17–0.92; p = 0.03). However, subgroup analysis demonstrated that no statistically significant reduction of Grade3–4 mucositis (RR,0.97; 95% CI,0.74–1.26; p = 0.80), Grade 2–4 acute xerostomia (RR,0.35; 95%CI,0.02–5.44; p = 0.45), or late xerostomia (RR,0.40; 95%CI,0.13–1.24; p = 0.11) and Grade 3–4 dysphagia (RR,0.23; 95%CI,0.01–4.78; p = 0.35) was observed in patients treated with concomitant chemoradiotherapy. Compared with placebo or observation, amifostine does not show tumor protective effect in complete response (RR,1.02; 95%CI,0.89–1.17; p = 0.76) and partial response (RR,0.90; 95%CI, 0.56–1.44; p = 0.66). For the hematologic side effect, no statistical difference of Grade 3–4 leucopenia (RR,0.60; 95%CI,0.35–1.05; p = 0.07), anemia (RR,0.80; 95%CI, 0.42–1.53; p = 0.50) and thrombocytopenia (RR,0.43; 95%CI,0.16–1.15; p = 0.09) were found between amifostine and control groups. The most common amifostine related side effects were nausea, emesis, hypotension and allergic with an average incidence rate (Grade 3–4) of 5%, 6%, 4% and 4% respectively. Conclusion This systematic review showed that amifostine significantly reduce the serious mucositis, acute/late xerastomia and dysphagia without protection of the tumor in HNSCC patients treated with radiotherapy. And the toxicities of amifostine were generally acceptable." @default.
• W2094341752 created "2016-06-24" @default.
• W2094341752 creator A5009487022 @default.
• W2094341752 creator A5050103020 @default.
• W2094341752 creator A5065628116 @default.
• W2094341752 creator A5078047572 @default.
• W2094341752 creator A5081243530 @default.
• W2094341752 creator A5089784531 @default.
• W2094341752 date "2014-05-02" @default.
• W2094341752 modified "2023-10-16" @default.
• W2094341752 title "Effect of Amifostine in Head and Neck Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials" @default.
• W2094341752 cites W1598602811 @default.
• W2094341752 cites W1894754434 @default.
• W2094341752 cites W1965811077 @default.
• W2094341752 cites W1968045554 @default.
• W2094341752 cites W1973434633 @default.
• W2094341752 cites W1977951246 @default.
• W2094341752 cites W1981897521 @default.
• W2094341752 cites W1990582908 @default.
• W2094341752 cites W1993896435 @default.
• W2094341752 cites W1995406926 @default.
• W2094341752 cites W1995996456 @default.
• W2094341752 cites W2002992903 @default.
• W2094341752 cites W2022101062 @default.
• W2094341752 cites W2024963005 @default.
• W2094341752 cites W2031004529 @default.
• W2094341752 cites W2038645302 @default.
• W2094341752 cites W2040672621 @default.
• W2094341752 cites W2043945205 @default.
• W2094341752 cites W2049199928 @default.
• W2094341752 cites W2081428711 @default.
• W2094341752 cites W2093023735 @default.
• W2094341752 cites W2095602776 @default.
• W2094341752 cites W2103804211 @default.
• W2094341752 cites W2106787323 @default.
• W2094341752 cites W2107328434 @default.
• W2094341752 cites W2113029111 @default.
• W2094341752 cites W2125435699 @default.
• W2094341752 cites W2138944577 @default.
• W2094341752 cites W2144354340 @default.
• W2094341752 cites W2155822213 @default.
• W2094341752 cites W2157823046 @default.
• W2094341752 cites W2157885764 @default.
• W2094341752 cites W2164157162 @default.
• W2094341752 cites W2166267558 @default.
• W2094341752 cites W2168701926 @default.
• W2094341752 cites W2268047913 @default.
• W2094341752 cites W2332946017 @default.
• W2094341752 cites W2912459008 @default.
• W2094341752 cites W4246602552 @default.
• W2094341752 cites W2149668984 @default.
• W2094341752 doi "https://doi.org/10.1371/journal.pone.0095968" @default.
• W2094341752 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4008569" @default.
• W2094341752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24788761" @default.
• W2094341752 hasPublicationYear "2014" @default.
• W2094341752 type Work @default.
• W2094341752 sameAs 2094341752 @default.
• W2094341752 citedByCount "103" @default.
• W2094341752 countsByYear W20943417522014 @default.
• W2094341752 countsByYear W20943417522015 @default.
• W2094341752 countsByYear W20943417522016 @default.
• W2094341752 countsByYear W20943417522017 @default.
• W2094341752 countsByYear W20943417522018 @default.
• W2094341752 countsByYear W20943417522019 @default.
• W2094341752 countsByYear W20943417522020 @default.
• W2094341752 countsByYear W20943417522021 @default.
• W2094341752 countsByYear W20943417522022 @default.
• W2094341752 countsByYear W20943417522023 @default.
• W2094341752 crossrefType "journal-article" @default.
• W2094341752 hasAuthorship W2094341752A5009487022 @default.
• W2094341752 hasAuthorship W2094341752A5050103020 @default.
• W2094341752 hasAuthorship W2094341752A5065628116 @default.
• W2094341752 hasAuthorship W2094341752A5078047572 @default.
• W2094341752 hasAuthorship W2094341752A5081243530 @default.
• W2094341752 hasAuthorship W2094341752A5089784531 @default.
• W2094341752 hasBestOaLocation W20943417521 @default.
• W2094341752 hasConcept C126322002 @default.
• W2094341752 hasConcept C141071460 @default.
• W2094341752 hasConcept C142724271 @default.
• W2094341752 hasConcept C168563851 @default.
• W2094341752 hasConcept C187960798 @default.
• W2094341752 hasConcept C204787440 @default.
• W2094341752 hasConcept C27081682 @default.
• W2094341752 hasConcept C2776530083 @default.
• W2094341752 hasConcept C2778424827 @default.
• W2094341752 hasConcept C2778496288 @default.
• W2094341752 hasConcept C2779387952 @default.
• W2094341752 hasConcept C2780596822 @default.
• W2094341752 hasConcept C44249647 @default.
• W2094341752 hasConcept C509974204 @default.
• W2094341752 hasConcept C71924100 @default.
• W2094341752 hasConcept C82789193 @default.
• W2094341752 hasConcept C90924648 @default.
• W2094341752 hasConcept C95190672 @default.
• W2094341752 hasConceptScore W2094341752C126322002 @default.
• W2094341752 hasConceptScore W2094341752C141071460 @default.
• W2094341752 hasConceptScore W2094341752C142724271 @default.
• W2094341752 hasConceptScore W2094341752C168563851 @default.

• next